Drug Type Biological products |
Synonyms V 565, V565 |
Target |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Crohn Disease | Phase 2 | US | 01 Dec 2016 | |
Crohn Disease | Phase 2 | AT | 01 Dec 2016 | |
Crohn Disease | Phase 2 | CA | 01 Dec 2016 | |
Crohn Disease | Phase 2 | CZ | 01 Dec 2016 | |
Crohn Disease | Phase 2 | DE | 01 Dec 2016 | |
Crohn Disease | Phase 2 | HU | 01 Dec 2016 | |
Crohn Disease | Phase 2 | NL | 01 Dec 2016 | |
Crohn Disease | Phase 2 | NO | 01 Dec 2016 | |
Crohn Disease | Phase 2 | PL | 01 Dec 2016 | |
Crohn Disease | Phase 2 | RS | 01 Dec 2016 |
Phase 2 | 125 | (V565) | ssvxwwblwg(ivsrmsmarn) = hlzibbmzfa gmxgzcches (vizqtgmvsl, ojwynmzxtp - grxvbjinns) View more | - | 22 Dec 2021 | ||
Placebo (Placebo) | ssvxwwblwg(ivsrmsmarn) = mhpkirtugm gmxgzcches (vizqtgmvsl, xctscenewd - ddppemzojm) View more | ||||||
NCT03705117 (Pubmed) Manual | Phase 1 | - | thzkwntczd(fjziguvbdg) = decreased by approximately 50% tvzahxqhty (lqvnhtjgyu ) | Positive | 01 Oct 2019 |